Kura Oncology (KURA) is set to present early data from the KOMET-001 Ph1/2a AML study of KO-539 at ASH in December. Abstracts will be posted online on 11/6. The primary drug being evaluated is KO-539, a small molecule inhibitor that blocks the intera...